After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, AKRO falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Akero Therapeutics Inc is $2.14B. A total of 0.44 million shares were traded on the day, compared to an average of 550.70K shares.
In the most recent transaction, Yale Catriona sold 9,061 shares of AKRO for 27.73 per share on Nov 15 ’24. After the transaction, the Chief Development Officer now owns 74,158 company shares. In a previous transaction on Nov 06 ’24, Yale Catriona sold 10,000 shares at 35.19 per share. AKRO shares that Chief Development Officer owns now total 74,158.
Among the insiders who bought shares, CATRIONA YALE acquired of 10,000 shares on Nov 06 ’24 at a per-share price of $32.74. In another insider transaction, Young Jonathan sold 50,716 shares at $31.57 per share on Nov 01 ’24. Company shares held by the Chief Operating Officer now total 216,286.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, AKRO has a high of $37.00 and a low of $15.32.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $10.61, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 4.83.
